Concise Prescribing Info
Prevention of nausea & vomiting associated w/ emetogenic chemotherapy, including high dose cisplatin, & radiotherapy in adults. Prevention & treatment of post-op nausea & vomiting in adults. Prevention of post-chemotherapy-induced nausea & vomiting in ped patients 4-18 yr. Prevention of post-chemotherapy- & radiotherapy-induced nausea & vomiting in elderly >65 yr.
Dosage/Direction for Use
Chemotherapy-induced nausea & vomiting Adult & elderly >65 yr Post-chemotherapy w/ highly emetogenic agent: After the 1st 24 hr, 8 mg every 8 hr for up to 5 days. Less emetogenic chemotherapy: Initial dose: 8 mg 1-2 hr prior to chemotherapy. Post-chemotherapy: 8 mg bd for to 5 days. Childn Post-chemotherapy: 4 mg every 8 hr for up to 5 days. Radiotherapy-induced nausea & vomiting Adult Initial dose: 8 mg 1-2 hr before radiotherapy. Post-radiotherapy: 8 mg every 8 hr for up to 5 days after a course of treatment. Post-op nausea & vomiting Adult Single dose 16 mg 1 hr prior to anaesth. Patient w/ moderate or severe hepatic impairment Reduce dosage. Max: 8 mg daily.
Hypersensitivity. Concomitant use w/ apomorphine.
Special Precautions
Cross-reactive hypersensitivity between different 5-HT3 antagonists. QTc interval prolongation & Torsade de pointes. Not effective in preventing motion-induced nausea & vomiting. Serotonin syndrome or neuroleptic syndrome-like events when co-administered w/ other serotonergic &/or neuroleptic drugs. Increased large bowel transit time. Patients w/ moderate or severe impairment of hepatic function. Women of childbearing potential are recommended to use effective contraception during & for 2 days after stopping treatment. Pregnancy & lactation. Not indicated for use in childn ≤3 yr.
Adverse Reactions
Headache, constipation, sensations of flushing or warmth.
Drug Interactions
Increased clearance & decreased blood conc w/ CYP3A4 inducers (eg, phenytoin, carbamazepine, rifampicin). Increased risk of QTc interval prolongation & Torsade de pointes w/ QTc-prolonging drugs. Avoid drugs that can disrupt electrolyte levels (eg, loop, thiazide & related diuretics, laxatives & enemas, amphotericin B, high dose corticosteroids). May reduce analgesic effect of tramadol. Profound hypotension & loss of consciousness w/ apomorphine HCl. Serotonin syndrome w/ serotonergic drugs (eg, triptans, SSRIs, SNRIs, lithium, sibutramine, fentanyl & its analogues, dextromethorphan, tramadol, tapentadol, meperidine, methadone, pertazocine. St. John's Wort), & w/ drugs which impair metabolism of serotonin (eg, MAOIs).
MIMS Class
Antiemetics / Supportive Care Therapy
ATC Classification
A04AA01 - ondansetron ; Belongs to the class of serotonin (5HT3) antagonists. Used for the prevention of nausea and vomiting.
pms-Ondansetron tab 4 mg
100's;2 × 5's
pms-Ondansetron tab 8 mg
100's;2 × 5's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in